Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

TARS

Tarsus Pharmaceuticals Inc

Apr 25 • 04:00PM ET

32.21

Dollar change -0.55
Percentage change -1.68	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT IHE IWC

Index	RUT	P/E	-	EPS (ttm)	-4.64	Insider Own	19.42%	Shs Outstand	34.21M	Perf Week	-1.95%
Market Cap	1.21B	Forward P/E	-	EPS next Y	-1.76	Insider Trans	-1.39%	Shs Float	30.22M	Perf Month	-4.82%
Income	-135.89M	PEG	-	EPS next Q	-1.18	Inst Own	75.27%	Short Float	26.14%	Perf Quarter	22.70%
Sales	17.45M	P/S	69.22	EPS this Y	11.75%	Inst Trans	1.81%	Short Ratio	10.87	Perf Half Y	140.19%
Book/sh	5.76	P/B	5.59	EPS next Y	56.92%	ROA	-55.01%	Short Interest	7.90M	Perf Year	124.62%
Cash/sh	6.07	P/C	5.31	EPS next 5Y	-	ROE	-69.71%	52W Range	12.57 - 40.40	Perf YTD	59.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-132.82%	ROI	-59.52%	52W High	-20.27%	Beta	1.10
Dividend TTM	-	Quick Ratio	6.85	Sales past 5Y	-17.43%	Gross Margin	85.48%	52W Low	156.25%	ATR (14)	1.86
Dividend Ex-Date	-	Current Ratio	6.93	EPS Y/Y TTM	-80.72%	Oper. Margin	-820.53%	RSI (14)	42.76	Volatility	5.24% 5.28%
Employees	244	Debt/Eq	0.16	Sales Y/Y TTM	-32.42%	Profit Margin	-778.89%	Recom	1.33	Target Price	52.33
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	-157.80%	Payout	-	Rel Volume	0.51	Prev Close	32.76
Sales Surprise	138.99%	EPS Surprise	4.53%	Sales Q/Q	30.76%	Earnings	Feb 27 BMO	Avg Volume	726.90K	Price	32.21
SMA20	-7.71%	SMA50	-4.85%	SMA200	43.16%	Trades		Volume	371,846	Change	-1.68%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Apr-23-24 08:30AM	Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon (GlobeNewswire)
Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Loading…
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
08:00AM	Loading…
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire)
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Jan-21-24 07:01AM	11 Stocks That Will Make You Rich in 5-10 Years (Insider Monkey)
Dec-21-23 03:32PM	Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade (Investor's Business Daily)
Dec-11-23 08:00AM	Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites (GlobeNewswire)
Dec-01-23 11:04PM	Insider Sell Alert: Tarsus Pharmaceuticals Inc's Dianne Whitfield Offloads 8,355 Shares (GuruFocus.com)
Nov-12-23 12:15PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire) -5.86%
Nov-01-23 06:35PM	Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (GlobeNewswire)
Sep-06-23 08:00AM	Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-30-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-24-23 09:00AM	Now Available XDEMVY (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
04:05PM	Loading…
Aug-10-23 04:05PM	Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-03-23 02:14PM	This Tarsus Pharmaceuticals Insider Increased Their Holding In The Last Year (Simply Wall St.)
Aug-01-23 10:30PM	Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -16.99%
Jul-31-23 04:29PM	Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire)
Jul-25-23 07:00AM	FDA Approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis (GlobeNewswire) -24.82%
Jul-20-23 02:04PM	Why Shares of Tarsus Pharmaceuticals Are Up Thursday (Motley Fool) +15.56%
Jul-19-23 08:34PM	Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains? (Zacks) +7.83%
10:13AM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Jun-12-23 08:30AM	Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis (GlobeNewswire)
Jun-05-23 08:30AM	Tarsus to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 04:05PM	Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
May-08-23 08:30AM	Tarsus Launches Dont Freak Out. Get Checked Out. Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers (GlobeNewswire)
May-05-23 08:22AM	Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price (Simply Wall St.)
May-03-23 04:30PM	Tarsus to Participate at the Bank of America 2023 Healthcare Conference (GlobeNewswire)
Apr-24-23 08:30AM	Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer (GlobeNewswire)
Apr-18-23 06:04AM	Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks) +5.25%
Apr-06-23 03:52PM	Shareholders in Tarsus Pharmaceuticals (NASDAQ:TARS) are in the red if they invested a year ago (Simply Wall St.)
Mar-17-23 06:28AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Mar-13-23 04:05PM	Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Mar-09-23 10:00AM	Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-02-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 11:44AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insiders placed bullish bets worth US$1.6m in the last 12 months (Simply Wall St.)
Jan-24-23 04:33AM	Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength? (Zacks)
Dec-16-22 07:00AM	Tarsus Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-15-22 12:45PM	Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease (Benzinga)
08:30AM	Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease (GlobeNewswire)
Dec-08-22 06:55AM	Institutional investors own a significant stake of 41% in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (Simply Wall St.)
Nov-11-22 06:03AM	Tarsus Pharmaceuticals Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.76 loss in 3Q 2021) (Simply Wall St.)
Nov-09-22 08:45AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Oct-25-22 08:30AM	Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 09:26AM	Tarsus Pharmaceuticals (NASDAQ:TARS) investors are sitting on a loss of 40% if they invested a year ago (Simply Wall St.)
Oct-11-22 08:30AM	Tarsus Announces Transition Plans for Board of Directors (GlobeNewswire)
Oct-06-22 08:30AM	Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair (GlobeNewswire)
Sep-29-22 08:30AM	Tarsus Launches Look at the Lids Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis (GlobeNewswire)
Sep-27-22 12:00PM	Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings (GlobeNewswire)
Sep-17-22 10:23AM	The Chief Medical Advisor & Director of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), Elizabeth Lin, Just Bought A Few More Shares (Simply Wall St.)
Sep-07-22 07:00AM	Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Aug-11-22 05:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-22 08:30AM	Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease (GlobeNewswire)
Jul-25-22 08:00AM	Certara Appoints Rosemary Crane as New Independent Board Member (GlobeNewswire)
Jun-29-22 06:51AM	Do Insiders Own Lots Of Shares In Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? (Simply Wall St.)
May-27-22 09:00AM	Tarsus to Present at the Jefferies 2022 Healthcare Conference (GlobeNewswire)
May-14-22 08:19AM	Analysts Just Shipped A Captivating Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Estimates (Simply Wall St.)
May-11-22 06:30AM	The Co-Founder & Independent Chairperson of the Board of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), D. Ackermann, Just Bought 8.3% More Shares (Simply Wall St.)
May-10-22 06:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +11.30%
04:05PM	Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
May-09-22 01:49PM	Further weakness as Tarsus Pharmaceuticals (NASDAQ:TARS) drops 39% this week, taking one-year losses to 63% (Simply Wall St.)
May-06-22 09:00AM	Tarsus to Present at Bank of America 2022 Healthcare Conference (GlobeNewswire) -8.05%
May-05-22 08:30AM	Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting (GlobeNewswire) -6.73%
May-03-22 03:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -6.79%
06:58AM	Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
May-02-22 07:01AM	Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire) -23.54%
07:00AM	Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year (GlobeNewswire)
Apr-29-22 09:23PM	Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Apr-26-22 08:30AM	Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting (GlobeNewswire)
Apr-21-22 03:05AM	E3 Metals Initiates Design of Field Pilot (PR Newswire)
Mar-14-22 04:05PM	Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements (GlobeNewswire) -5.90%
Mar-09-22 05:00PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-03-22 09:00AM	Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Feb-02-22 04:30PM	Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03 (GlobeNewswire) -14.15%
07:00AM	Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility (GlobeNewswire)
Jan-04-22 09:00AM	Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors (GlobeNewswire)
Nov-23-21 04:30PM	Tarsus to Participate at Upcoming Virtual Investor Conferences (GlobeNewswire) +7.72%
Nov-10-21 04:30PM	Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021 (GlobeNewswire)
Nov-09-21 04:05PM	Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements (GlobeNewswire)
Nov-05-21 12:04PM	Notable Tarsus Pharmaceuticals Insider Makes $160K Sale (Benzinga)
Nov-04-21 11:28AM	Tarsus Pharmaceuticals Insider Sold $160K In Company Stock (Benzinga)
09:45AM	Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting (GlobeNewswire)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '24	Sale	30.60	10,415	318,699	26,456	Mar 19 07:05 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '24	Sale	30.60	4,879	149,297	64,767	Mar 19 07:03 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '24	Sale	30.60	4,766	145,840	54,075	Mar 19 07:08 PM
Wahl Bryan	General Counsel	Mar 18 '24	Sale	30.60	4,436	135,742	40,951	Mar 19 07:05 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '24	Sale	30.60	4,314	132,008	34,181	Mar 19 07:04 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 27 '23	Sale	20.22	8,000	161,760	830,106	Dec 29 05:08 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 20 '23	Sale	20.27	40,000	810,623	838,106	Dec 22 05:30 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Dec 20 '23	Sale	20.00	2,252	45,040	2,251	Dec 22 05:32 PM
Goldberg Andrew D.	Director	Dec 15 '23	Buy	18.96	1,000	18,960	3,000	Dec 19 06:30 PM
Wahl Bryan	General Counsel	Nov 30 '23	Sale	16.31	8,356	136,286	31,966	Dec 01 04:55 PM
Whitfield Dianne C.	Chief Human Resources Officer	Nov 30 '23	Sale	16.31	8,355	136,270	26,784	Dec 01 04:58 PM
Whitfield Dianne C.	Chief Human Resources Officer	Nov 29 '23	Option Exercise	0.00	23,920	0	35,139	Dec 01 04:58 PM
Wahl Bryan	General Counsel	Nov 29 '23	Option Exercise	0.00	23,920	0	40,322	Dec 01 04:55 PM
Azamian Bobak R.	President/CEO and Board Chair	Nov 15 '23	Sale	18.37	8,000	146,933	878,106	Nov 17 04:50 PM
Azamian Bobak R.	President/CEO and Board Chair	Oct 18 '23	Sale	13.24	8,000	105,920	886,106	Oct 20 04:41 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Oct 05 '23	Sale	18.00	1,604	28,872	4,503	Oct 06 05:21 PM
Azamian Bobak R.	President/CEO and Board Chair	Sep 20 '23	Sale	17.21	8,000	137,680	894,106	Sep 22 05:30 PM
Azamian Bobak R.	President/CEO and Board Chair	Aug 23 '23	Sale	17.23	8,000	137,840	902,106	Aug 25 05:12 PM
Lin Elizabeth Yeu	Director	Aug 15 '23	Buy	16.80	9,506	159,701	15,866	Aug 17 06:02 PM
Azamian Bobak R.	President/CEO and Board Chair	Jul 19 '23	Sale	20.01	103,900	2,078,984	910,106	Jul 21 05:42 PM
Mottiwala Aziz	Chief Commercial Officer	Jul 19 '23	Sale	20.05	2,400	48,120	45,806	Jul 21 05:46 PM
Azamian Bobak R.	President/CEO and Board Chair	Jul 12 '23	Sale	17.35	9,000	156,150	1,014,006	Jul 14 04:40 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 21 '23	Sale	18.63	8,000	149,040	1,023,006	Jun 23 04:29 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 14 '23	Sale	18.58	9,000	167,220	1,031,006	Jun 16 04:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 08 '23	Sale	20.01	3,100	62,031	1,040,006	Jun 12 05:40 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 08 '23	Sale	20.00	100	2,000	48,086	Jun 12 05:25 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 07 '23	Sale	19.34	2,500	48,350	48,186	Jun 08 07:16 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 06 '23	Sale	18.61	2,143	39,881	50,686	Jun 08 07:16 PM
Azamian Bobak R.	President/CEO and Board Chair	May 17 '23	Sale	15.90	8,000	127,200	1,043,106	May 19 07:08 PM
Azamian Bobak R.	President/CEO and Board Chair	May 10 '23	Sale	16.80	9,000	151,200	1,051,106	May 12 05:08 PM
Azamian Bobak R.	President/CEO and Board Chair	May 01 '23	Sale	15.10	5,841	88,199	1,060,106	May 02 07:06 PM
Azamian Bobak R.	President/CEO and Board Chair	Apr 28 '23	Sale	15.13	4,278	64,726	1,065,947	May 02 07:06 PM

Open in Screener

ALXO

Alx Oncology Holdings Inc

Apr 25 • 04:00PM ET

16.87

Dollar change +0.65
Percentage change 4.01	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ALXO Alx Oncology Holdings Inc daily Stock Chart

Held by: IWM VTI VXF IWN IBB SCHA VFMO VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-3.74	Insider Own	45.39%	Shs Outstand	49.95M	Perf Week	7.18%
Market Cap	851.94M	Forward P/E	-	EPS next Y	-2.73	Insider Trans	-0.36%	Shs Float	27.58M	Perf Month	50.76%
Income	-160.81M	PEG	-	EPS next Q	-0.82	Inst Own	57.41%	Short Float	13.40%	Perf Quarter	16.51%
Sales	0.00M	P/S	-	EPS this Y	14.60%	Inst Trans	1.06%	Short Ratio	7.80	Perf Half Y	137.61%
Book/sh	3.80	P/B	4.44	EPS next Y	14.38%	ROA	-58.58%	Short Interest	3.69M	Perf Year	207.29%
Cash/sh	3.62	P/C	4.66	EPS next 5Y	-	ROE	-70.97%	52W Range	3.94 - 17.42	Perf YTD	13.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-50.98%	ROI	-78.31%	52W High	-3.16%	Beta	1.32
Dividend TTM	-	Quick Ratio	5.24	Sales past 5Y	-8.67%	Gross Margin	-	52W Low	328.64%	ATR (14)	1.18
Dividend Ex-Date	-	Current Ratio	5.24	EPS Y/Y TTM	-23.35%	Oper. Margin	0.00%	RSI (14)	66.99	Volatility	8.77% 8.60%
Employees	72	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.29	Target Price	20.17
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-23.17%	Payout	-	Rel Volume	1.09	Prev Close	16.22
Sales Surprise	-	EPS Surprise	-6.08%	Sales Q/Q	-	Earnings	Mar 07 AMC	Avg Volume	473.44K	Price	16.87
SMA20	28.65%	SMA50	23.46%	SMA200	68.52%	Trades		Volume	509,819	Change	4.01%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-08-24	Downgrade	Stifel	Buy → Hold	$10 → $14
Dec-08-23	Upgrade	Jefferies	Hold → Buy	$8 → $18
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$65 → $25
Sep-30-21	Initiated	Stifel	Buy	$106
May-05-21	Resumed	Credit Suisse	Outperform	$98
Apr-26-21	Resumed	Credit Suisse	Outperform	$98
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy	$100
Aug-11-20	Initiated	Piper Sandler	Overweight	$55
Aug-11-20	Initiated	Jefferies	Buy	$50
Aug-11-20	Initiated	Credit Suisse	Outperform	$53
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight	$64

Show Previous Ratings

Apr-24-24 10:00AM	ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-11-24 09:30AM	ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study (Zacks) +11.04%
Apr-09-24 05:30PM	ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ( R/R B-NHL ) (GlobeNewswire)
Apr-06-24 01:33AM	ALX Oncology Holdings Inc (ALXO) Insider Sells Shares (GuruFocus.com)
Mar-08-24 03:48PM	ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer (Benzinga) -6.34%
10:53PM	Loading…
Mar-07-24 10:53PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023 (InvestorPlace) +9.95%
10:41PM	ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending (GuruFocus.com)
04:03PM	ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting (GlobeNewswire)
Jan-03-24 08:00AM	ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 04:21PM	7 Small-Cap Stocks That Wall Street Loves for Good Reason (InvestorPlace) +18.04%
Nov-13-23 04:47PM	ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) +8.08%
04:05PM	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire)
Oct-10-23 04:05PM	ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +16.24%
04:59AM	Loading…
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks) +27.38%
Oct-05-23 10:58AM	Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More (Zacks)
08:00AM	ALX Oncology Announces Pricing of Public Offering (GlobeNewswire)
Oct-04-23 04:10PM	ALX Oncology Announces Proposed Public Offering (GlobeNewswire) -15.05%
11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
Oct-03-23 11:15AM	Why ALX Oncology Stock Is Skyrocketing Today (Motley Fool) +56.13%
09:36AM	Midday movers: McCormick Airbnb, Point Biopharma and more (Investing.com)
06:00AM	ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Oct-02-23 04:05PM	ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Sep-06-23 08:00AM	ALX Oncology Realigns Executive Leadership Team (GlobeNewswire) +6.37%
Aug-31-23 07:00AM	ALX Oncology Announces September Investor Conference Participation (GlobeNewswire)
Aug-14-23 07:31PM	While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals)
Aug-10-23 04:01PM	ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update (GlobeNewswire)
09:55AM	ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jun-26-23 07:00AM	ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer (GlobeNewswire)
04:01PM	Loading…
May-11-23 04:01PM	ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
May-09-23 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer (GlobeNewswire) +6.36%
Apr-25-23 07:00AM	ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma (GlobeNewswire)
Apr-19-23 11:36AM	These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler (TipRanks) +6.44%
Mar-14-23 08:00AM	ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (PR Newswire) -6.75%
Mar-13-23 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (GlobeNewswire)
Mar-09-23 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) -5.93%
Feb-16-23 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer (GlobeNewswire)
Jan-05-23 07:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023 (GlobeNewswire)
Jan-03-23 07:00AM	ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-22 10:00AM	ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia (GlobeNewswire) +5.12%
Nov-29-22 07:00AM	ALX Oncology Appoints Scott Garland to its Board of Directors (GlobeNewswire) +7.25%
Nov-08-22 04:01PM	ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Nov-03-22 09:00AM	ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting (GlobeNewswire)
Nov-02-22 07:00AM	ALX Oncology Announces Upcoming Investor Conference Participation (GlobeNewswire)
Oct-31-22 07:00AM	ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept (GlobeNewswire)
Oct-05-22 08:01AM	ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-21-22 04:01PM	ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-01-22 07:00AM	ALX Oncology Announces Upcoming Investor Conference Participation (GlobeNewswire)
Aug-16-22 09:45AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer (PR Newswire)
Aug-15-22 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer (GlobeNewswire)
Aug-11-22 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer (GlobeNewswire)
Aug-08-22 04:01PM	ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Aug-01-22 07:00AM	ALX Oncologys Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jun-29-22 08:44AM	ALX's stock is up 11% after getting orphan-drug designation for cancer drug (MarketWatch)
07:00AM	ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia (GlobeNewswire)
Jun-22-22 09:00AM	Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference (GlobeNewswire)
Jun-03-22 07:00AM	ALX Oncology Announces Evorpacept Clinical Program Updates (GlobeNewswire)
Jun-01-22 07:00AM	ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference (GlobeNewswire)
Apr-12-22 07:00AM	ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors (GlobeNewswire)
Mar-02-22 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer (GlobeNewswire)
Feb-28-22 07:00AM	ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) +7.54%
Feb-03-22 07:01PM	3 Strong Buy Small-Cap Stocks That Are Too Cheap to Ignore (TipRanks) -5.08%
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... (GuruFocus.com) -11.83%
Jan-28-22 12:44PM	ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC (Zacks) +5.85%
08:02AM	ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer (Benzinga)
Jan-27-22 05:51PM	ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer (GlobeNewswire)
Jan-19-22 06:23AM	New Strong Sell Stocks for January 19th (Zacks)
Jan-10-22 06:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022 (GlobeNewswire)
Jan-04-22 07:00AM	ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.62%
Dec-14-21 09:00AM	DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia (PR Newswire)
Dec-13-21 01:58PM	ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation (Benzinga) -24.20%
Dec-12-21 09:00AM	ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome (GlobeNewswire)
Nov-11-21 04:05PM	ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Nov-09-21 11:13AM	ALX Oncology Falls After Updated Data For Solid Tumors Candidate (Benzinga) -21.47%
07:00AM	ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors (GlobeNewswire)
Nov-04-21 09:00AM	ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting (GlobeNewswire) -15.47%
Nov-02-21 09:00AM	ALX Oncology Announces Upcoming Virtual Investor Conference Participation (GlobeNewswire)
Oct-21-21 11:19AM	President And CEO Of Alx Oncology Holdings Sold $910K In Stock (Benzinga)
07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia (GlobeNewswire)
Oct-07-21 07:00AM	ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio (GlobeNewswire) -6.68%
Oct-01-21 08:00AM	ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire)
Sep-16-21 07:00AM	ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma (GlobeNewswire)
Sep-14-21 07:00AM	Lightstone Ventures Raises $375 Million Fund (PR Newswire)
Sep-07-21 07:00AM	ALX Oncology Announces Upcoming Virtual Investor Conference Participation (GlobeNewswire)
Aug-27-21 06:55AM	The 3 Best Biotech Stocks to Buy Right Now (Motley Fool)
Aug-12-21 04:05PM	ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Jul-28-21 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jul-15-21 12:00PM	ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know (Zacks)
01:36AM	Read This Before Selling ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares (Simply Wall St.)
Jul-12-21 06:07AM	ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Jul-06-21 09:15AM	ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer (Benzinga) +9.70%
Jul-03-21 07:15AM	ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer (GlobeNewswire)
Jun-14-21 07:00AM	ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies (GlobeNewswire)
Jun-10-21 07:00AM	ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer (GlobeNewswire)
May-18-21 07:00AM	ALX Oncology Announces Upcoming Virtual Investor Conference Participation (GlobeNewswire)
May-17-21 04:05PM	ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
May-10-21 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma (GlobeNewswire) -5.03%
Apr-21-21 04:05PM	ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer (GlobeNewswire) +6.54%
Apr-16-21 01:41AM	Companies Like ALX Oncology Holdings (NASDAQ:ALXO) Are In A Position To Invest In Growth (Simply Wall St.)

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pons Jaume	PRESIDENT & CSO	Apr 16 '24	Option Exercise	0.99	25,846	25,588	654,205	Apr 18 04:49 PM
Pons Jaume	PRESIDENT & CSO	Apr 16 '24	Sale	14.20	50,000	710,195	604,205	Apr 18 04:49 PM
Pons Jaume	PRESIDENT & CSO	Apr 04 '24	Sale	11.15	20,000	223,036	628,359	Apr 05 05:37 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Mar 14 '24	Buy	11.31	4,400	49,771	171,620	Mar 18 04:06 PM
Pinto Shelly	SVP, Finance and CAO	Jan 04 '24	Sale	13.60	2,717	36,957	78,591	Jan 05 04:03 PM
Pons Jaume	President & CSO	Dec 29 '23	Sale	15.04	7,179	107,972	618,359	Jan 03 04:17 PM
Randolph Sophia	Chief Medical Officer	Dec 29 '23	Sale	15.04	3,128	47,045	312,349	Jan 03 04:25 PM
GARCIA PETER S	Chief Financial Officer	Dec 29 '23	Sale	15.04	1,893	28,471	85,348	Jan 03 04:20 PM
Pinto Shelly	SVP, Finance and CAO	Dec 29 '23	Sale	15.04	1,631	24,530	81,308	Jan 03 04:28 PM
Pinto Shelly	VP, Finance and CAO	Jul 06 '23	Sale	6.52	7,345	47,889	55,713	Jul 07 04:09 PM
Pons Jaume	President & CEO	Jun 30 '23	Sale	7.34	3,208	23,547	536,538	Jul 05 05:07 PM
Randolph Sophia	Chief Medical Officer	Jun 30 '23	Sale	7.34	1,605	11,781	281,477	Jul 05 05:09 PM
GARCIA PETER S	Chief Financial Officer	Jun 30 '23	Sale	7.34	887	6,511	54,738	Jul 05 05:00 PM
Pinto Shelly	VP, Finance and CAO	Jun 30 '23	Sale	7.34	466	3,420	63,058	Jul 05 05:05 PM
Randolph Sophia	Chief Medical Officer	Jun 09 '23	Option Exercise	3.75	12,829	48,171	283,082	Jun 13 04:38 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

TARS

Tarsus Pharmaceuticals Inc

ALXO

Alx Oncology Holdings Inc

Upgrade your FINVIZ experience